NVO - Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval | Benzinga
On Friday, China’s National Medical Products Administration (NMPA) approved Eli Lilly And Co (NYSE:LLY) Tirzepatide for long-term weight management.
It is suitable for long-term weight management of adults whose body mass index (BMI) meets the following requirements based on diet control and increased exercise: ?28 kg/m2 (obese) or ?24 kg/m2 (overweight) with at least one condition.
Tirzepatide is known in the U.S. as Mounjaro for diabetes and Zepbound for weight loss.